patient
healthcar
worker
educ
risk
method
prevent
acquisit
pathogen
method
discuss
section
infect
higher
risk
recurr
includ
mycobacteriosi
tuberculosi
other
aspergillosi
pneumocystosi
cytomegaloviru
herp
simplex
varicellazost
viru
toxoplasmosi
strongyloidiasi
renal
failur
increas
risk
sever
mucos
patient
multipl
myeloma
receiv
melphalanbas
condit
regimen
e
need
addit
chemotherapi
lymphoma
acut
myeloid
leukemia
usual
relat
relaps
underli
diseas
wherea
multipl
myeloma
addit
chemotherapi
usual
part
treatment
strategi
f
vitro
manipul
stem
cell
decreas
content
tcell
increas
durat
neutropenia
earli
posttranspl
period
delay
tcell
immun
reconstitut
transplant
infect
frequent
complic
lead
caus
morbid
mortal
patient
hematolog
malign
problem
associ
manag
infect
patient
includ
dif
fi
culti
earli
diagnosi
clinic
sign
infect
subtl
low
perform
diagnost
test
suboptim
respons
treatment
recoveri
host
defens
key
factor
resolut
infect
prevent
infect
reli
infect
control
measur
antimicrobi
chemoprophylaxi
infect
control
measur
safe
alway
effect
use
antimicrobi
agent
prophylaxi
infect
devoid
problem
wide
use
may
increas
possibl
develop
resist
select
resist
organ
increas
toxic
cost
therefor
attempt
administ
antimicrobi
agent
accompani
fl
ection
potenti
bene
fi
ts
risk
prophylaxi
gener
higher
incid
infect
bene
fi
cial
like
antimicrobi
prophylaxi
likewis
shorter
period
risk
therefor
predict
durat
prophylaxi
higher
possibl
prophylaxi
work
howev
predict
incid
infect
simpl
requir
analysi
variou
factor
includ
patient
prior
exposur
pathogen
underli
diseas
previou
current
treatment
comorbid
geograph
area
other
therefor
three
question
critic
de
fi
ning
appropri
antimicrobi
prophylaxi
risk
infect
pathogen
predomin
set
period
risk
tabl
provid
risktarget
approach
prophylaxi
infect
patient
hematolog
malign
tabl
present
frequent
pathogen
respons
infect
accord
type
immunod
fi
cienci
present
chapter
describ
variou
strategi
direct
prevent
infect
patient
hematolog
malign
accord
riskbas
strategi
risk
assess
underli
diseas
eg
age
initi
white
blood
cell
count
cytogenet
immunophenotyp
rapid
cytoreduct
acut
lymphoid
leukemia
advanc
age
de
novo
vs
secondari
leukemia
prior
myelodysplasia
cytogenet
gene
mutat
pro
fi
le
acut
myeloid
leukemia
mutat
statu
immunoglobulin
vh
gene
chromosom
abnorm
chronic
lymphocyt
leukemia
b
common
diseaserel
immunosuppress
includ
hypogammaglobulinemia
multipl
myeloma
lowgrad
bcell
nonhodgkin
lymphoma
chronic
lymphocyt
leukemia
tcell
mediat
immunod
fi
cienci
hodgkin
lymphoma
certain
type
nonhodgkin
lymphoma
neutrophil
dysfunct
acut
myeloid
leukemia
myelodysplasia
handwash
remain
simplest
effect
measur
prevent
acquisit
organ
patient
patient
healthcar
worker
hcw
wash
hand
eat
smoke
insert
remov
contact
lens
use
restroom
blow
nose
cough
sneez
handl
dirti
item
soil
gauss
garbag
touch
anim
addit
healthcar
worker
also
wash
hand
patient
surfac
thoroughli
clean
includ
wrist
palm
back
hand
fi
nger
fi
ngernail
prefer
alcoholbas
hand
rub
howev
hand
visibl
dirti
soil
blood
bodi
fl
uid
soap
water
best
clean
hand
addit
recommend
includ
remov
ring
prior
handwash
keep
nail
short
clean
avoid
use
arti
fi
cial
nail
may
carri
pathogen
skin
fl
ora
could
potenti
sourc
infect
patient
keep
skin
clean
daili
bath
use
antisept
solut
special
attent
potenti
portal
infect
perineum
cathet
site
oral
fl
ora
lead
infect
especi
set
sever
mucos
radiotherapi
patient
graft
vs
host
diseas
gvhd
recommend
maintain
good
oral
dental
hygien
includ
oral
rins
time
day
steril
water
normal
salin
sodium
bicarbon
b
tooth
brush
least
twice
day
soft
ultrasoft
toothbrush
swab
less
effect
use
patient
toler
brush
pet
owner
follow
follow
recommend
avoid
contact
young
anim
pet
higher
risk
shed
salmonella
spp
campylobact
spp
higher
incid
diarrhea
b
obtain
veterinarian
consult
new
pet
adopt
yearli
thereaft
c
keep
pet
vaccin
current
keep
pet
feed
area
clean
litter
box
away
kitchen
eat
area
e
feed
pet
highqual
commerci
pet
food
cook
egg
poultri
meat
product
pasteur
dairi
product
avoid
access
bowl
toilett
garbag
f
supervis
pet
outdoor
prevent
contact
pet
fece
g
prevent
anim
roam
tickinfest
wood
h
wash
hand
handl
pet
avoid
contact
pet
fece
bird
drop
avoid
contact
anim
diarrhea
dog
expos
show
kennel
wild
bird
especi
pigeon
bird
avian
tuberculosi
reptil
high
carriag
shed
salmonella
spp
swine
sourc
b
bronchiseptica
j
keep
pet
away
face
wound
k
trim
pet
nail
short
l
notifi
physician
immedi
patient
bitten
injur
pet
instruct
kid
share
kiss
classroom
pet
n
clean
cage
wear
particul
mask
avoid
shake
cage
high
risk
patient
follow
addit
precaut
prevent
seriou
infect
summar
tabl
clean
refriger
regularli
discard
food
day
age
especi
salad
dress
sauc
milk
egg
product
condiment
process
meat
bacon
never
use
can
food
swollen
dent
rust
toss
chees
food
moldi
cut
fresh
chees
small
portion
store
separ
freezer
take
use
quickli
keep
cold
food
cold
hot
food
hot
prepar
food
hand
kept
away
hair
mouth
nose
possibl
ring
jewelri
remov
may
harbor
germ
tri
limit
touch
food
hand
use
tong
fork
possibl
cut
raw
meat
soak
cut
board
utensil
min
solut
one
part
bleach
eight
nine
part
water
one
ounc
bleach
cup
water
food
go
cook
prepar
fi
rst
way
raw
meat
poultri
prepar
wash
fruit
veget
well
keep
food
prepar
surfac
clean
use
good
dishwash
deterg
work
surfac
often
especi
handl
raw
meat
chicken
fi
sh
never
let
cat
anim
work
surfac
prepar
food
diarrhea
vomit
open
infect
sore
put
leftov
food
fridg
right
away
divid
larg
leftov
individu
contain
avoid
repeat
warm
raw
egg
sometim
use
restaurantprepar
caesar
salad
dress
homemad
mayonnais
eggnog
dri
uncook
undercook
meat
seafood
poultri
includ
medium
rare
steak
game
pickl
fi
sh
oyster
food
deli
cold
cut
hot
dog
tofu
sausag
bacon
cold
smoke
fi
sh
lox
unpasteur
commerci
fruit
veget
juic
unpasteur
milk
chees
product
soft
age
chees
feta
brie
camembert
bluevein
mexicanstyl
chees
refriger
cheesebas
salad
dress
eg
blue
chees
cream
chees
cottag
chees
yogurt
provid
contain
lactobacillusspp
ok
eat
unwash
raw
veget
fruit
end
visibl
mold
unpasteur
honey
beer
raw
uncook
brewer
yeast
miso
product
eg
miso
soup
temp
tempeh
matetea
moldi
outdat
food
product
herbal
prepar
nutrient
supplement
air
qualiti
import
prevent
infect
highrisk
patient
airborn
organ
mold
aspergillu
spp
fi
lament
fungi
legionella
spp
mycobacterium
tuberculosi
patient
high
risk
invas
aspergillosi
ia
place
seal
room
hepa
fi
lter
central
pointinus
posit
pressur
air
fl
ow
direct
air
intak
one
side
room
air
exhaust
opposit
side
system
abl
make
air
exchang
per
hour
group
repres
mostli
patient
receiv
induct
chemotherapi
acut
myeloid
leukemia
aml
preengraft
period
postallogen
hematopoiet
cell
transplant
hct
conidia
level
outdoor
air
vari
wide
cfu
winter
fall
certain
area
safe
concentr
airborn
fungi
establish
probabl
depend
patient
immun
statu
ef
fi
caci
hepa
fi
lter
prevent
entri
contamin
outsid
air
hospit
con
fi
rmed
demolit
build
despit
increas
number
conidia
fi
lament
fungi
conidia
found
hepafi
lter
equip
area
construct
renov
may
increas
concentr
airborn
fungi
guidelin
develop
activ
take
place
close
area
highrisk
patient
care
portabl
hepa
fi
lter
decreas
concentr
airborn
fungal
spore
use
success
prevent
occurr
fungal
infect
build
construct
howev
gener
agre
less
ef
fi
cient
central
pointinus
hepa
fi
lter
airborn
fungi
shown
secondarili
aerosol
water
sourc
therefor
prevent
measur
limit
exposur
water
decreas
airborn
concentr
fungal
pathogen
see
section
antifung
prophylaxi
although
data
exist
support
role
steril
lowlevel
microbialcont
cfuml
nonpathogen
organ
diet
patient
hematolog
malign
practic
gener
recommend
recent
publish
random
studi
compar
cook
uncook
diet
patient
undergo
induct
remiss
aml
differ
rate
episod
major
infect
death
hospit
water
system
reservoir
legionella
spp
bacteria
opportunist
mold
especi
aspergillu
spp
fusarium
spp
exophiala
jeanselmei
potenti
mode
acquisit
infect
includ
contamin
intraven
solut
direct
contact
skin
breakdown
aerosol
fungal
spore
measur
prevent
occurr
infect
depend
mode
acquisit
gener
recommend
patient
risk
infect
avoid
direct
exposur
contamin
water
addit
speci
fi
c
measur
test
includ
use
pointinus
water
fi
lter
legionella
spp
clean
waterrel
structur
prevent
aerosol
fungi
infect
transmit
hcw
patient
risk
transmiss
high
varicella
zoster
vzv
viral
conjunct
measl
tuberculosi
intermedi
fl
uenza
mump
parvoviru
pertussi
respiratori
syncyti
viru
rsv
rotaviru
rubella
therefor
hcw
previous
mention
infect
herp
simplex
viru
hsv
lesion
lip
fi
nger
contact
patient
hcw
care
patient
hematolog
cancer
immun
rubella
measl
mump
fl
uenza
chickenpox
addit
alreadi
recommend
tetanu
hepat
b
immun
recommend
immun
precaut
appli
hcw
also
appli
close
contact
patient
hematolog
cancer
immun
hepat
b
highli
recommend
sexual
contact
patient
addit
immun
hepat
consid
household
patient
chronic
liver
diseas
live
endem
area
oral
polio
vaccin
contraind
household
patient
hematolog
cancer
sinc
live
poliovirus
transmit
caus
diseas
immunocompromis
patient
especi
fi
rst
month
vaccin
patient
hematolog
cancer
also
avoid
exposur
individu
vesicular
rash
secondari
chickenpox
immun
prevent
vzv
diseas
sexual
activ
patient
avoid
unprotect
sex
period
signi
fi
cant
immunosuppress
reduc
risk
exposur
cmv
hsv
hiv
hpv
hbv
hbc
sexual
transmit
infect
procedur
break
integr
natur
barrier
skin
mucosa
avoid
possibl
fix
orthodont
applianc
space
maintain
worn
period
neutropenia
avoid
oral
trauma
infect
enema
suppositori
rectal
temperatur
check
orand
rectal
examin
contraind
necessari
dental
procedur
perform
prior
chemotherapi
allow
proper
heal
neutropenia
mucos
develop
bone
marrow
biopsi
done
asept
avoid
cellul
osteomyel
recommend
insert
indwel
devic
includ
care
clean
steril
instrument
devic
particularli
reusabl
one
guidelin
prevent
intravascular
devicerel
infect
howev
solid
evid
support
guidelin
prevent
intravascular
devicerel
infect
lack
antimicrobi
prophylaxi
may
primari
prevent
target
individu
infect
past
secondari
prevent
use
avoid
recurr
infect
individu
previous
infect
bacteri
infect
occur
frequent
two
set
neutropenia
hypogammaglobulinemia
shown
tabl
common
bacteri
infect
patient
neutropenia
includ
staphylococci
enterococci
viridan
streptococci
among
gramposit
bacteria
enterobacteria
nonfer
bacteria
especi
pseudomona
aeruginosa
acinetobact
spp
stenotrophomona
spp
among
gramneg
bacteria
gramneg
bacteremia
may
associ
high
mortal
rate
strategi
antibacteri
prophylaxi
neutropenia
focus
mostli
prevent
occurr
gramneg
bacteremia
quinolon
extens
studi
metaanalysi
pool
data
trial
show
quinolon
reduc
incid
fever
document
infect
mortal
associ
infect
major
concern
develop
resist
anoth
metaanalysi
examin
effect
quinolon
prophylaxi
microbi
resist
differ
incid
colon
resist
organ
rate
infect
caus
resist
pathogen
data
howev
must
interpret
caution
rate
resist
differ
among
differ
institut
citi
countri
gener
rule
clinician
decid
give
prophylaxi
quinolon
neutropen
patient
care
attent
develop
resist
advis
anoth
concern
use
quinolon
prophylaxi
increas
incid
infect
caus
gramposit
organ
notabl
viridan
streptococci
great
concern
relat
infect
may
occasion
evolv
shock
respiratori
failur
although
infect
may
prevent
penicillin
macrolid
strain
resist
agent
use
glycopeptid
gener
recommend
prophylaxi
tabl
show
usual
dose
quinolon
prophylaxi
bacteri
infect
neutropen
patient
hypogammaglobulinemia
frequent
chronic
lymphocyt
leukemia
cll
multipl
myeloma
allogen
hct
recipi
develop
gvhd
patient
greater
risk
develop
bacteri
infect
particularli
encapsul
bacteria
intraven
immunoglobulin
mgkg
everi
week
may
effect
prevent
bacteri
infect
recommend
support
random
control
studi
howev
sinc
use
costli
intraven
immunoglobulin
reserv
select
popul
patient
repeat
episod
sever
infect
cheaper
altern
immunoglobulin
give
quinolon
prophylaxi
levofl
oxacin
mgday
moxi
fl
oxacin
mgday
sulfamethoxazoletrimethoprim
tmpsmx
primari
prophylaxi
invas
candidiasi
indic
neutropen
patient
allogen
hct
recipi
two
random
clinic
trial
rct
show
fl
uconazol
reduc
frequenc
super
fi
cial
system
candidiasi
well
infectionrel
mortal
one
trial
fl
uconazol
given
day
posttranspl
post
hoc
analysi
trial
shown
fl
uconazol
associ
prolong
protect
invas
candidiasi
even
beyond
period
prophylaxi
bene
fi
prophylaxi
invas
candidiasi
appar
set
patient
acut
leukemia
howev
ineffect
fl
uconazol
nonhsct
neutropen
patient
probabl
relat
heterogen
popul
neutropen
patient
studi
differ
incid
invas
candidiasi
rather
absenc
ef
fi
caci
gener
higher
risk
patient
develop
sever
mucos
neutropenia
higher
risk
invas
candidiasi
fluconazol
drug
choic
usual
dose
mg
daili
fluconazol
effect
prevent
infect
caus
candida
speci
candida
krusei
intrins
resist
fl
uconazol
candida
glabrata
exhibit
minim
inhibitori
concentr
mic
higher
speci
consequ
fl
uconazol
recommend
prevent
infect
due
two
speci
fl
uconazol
itraconazol
oral
solut
capsul
voriconazol
posaconazol
micafungin
voriconazol
effect
prevent
occurr
invas
candidiasi
neutropenia
ia
usual
occur
context
prolong
day
profound
neutropenia
patient
receiv
induct
therapi
aml
myelodysplasia
md
myeloabl
condit
regimen
allogen
hct
addit
hct
recipi
gvhd
high
risk
ia
patient
sever
tcell
mediat
immunod
fi
cienci
rather
profound
prolong
neutropenia
main
risk
factor
recent
case
ia
diagnos
patient
hematolog
malign
includ
patient
cll
receiv
treatment
alemtuzumab
patient
multipl
myeloma
set
amlmd
posaconazol
mg
per
day
superior
fl
uconazol
itraconazol
oral
solut
larg
random
control
trial
consid
drug
choic
antiaspergillu
prophylaxi
contrast
reduct
incid
ia
observ
trial
compar
itraconazol
fl
uconazol
itraconazol
associ
advers
event
recent
metaanalysi
itraconazol
trial
suggest
reduct
aspergillu
infect
certain
threshold
bioavail
dose
use
abil
prevent
invas
fungal
infect
associ
trough
itraconazol
concentr
ngml
best
achiev
iv
formul
follow
oral
solut
gastrointestin
function
intact
oral
capsul
formul
suffer
errat
bioavail
best
avoid
allogen
hct
recipi
itraconazol
oral
solut
result
reduct
frequenc
ia
two
trial
patient
discontinu
itraconazol
gastrointestin
side
effect
trial
prophylaxi
use
earli
preengraft
postengraft
period
anoth
rct
compar
posaconazol
fl
uconazol
allogen
hct
recipi
develop
gvhd
although
primari
endpoint
incid
invas
fungal
infect
random
day
prophylaxi
achiev
posaconazol
signi
fi
cantli
reduc
incid
ia
mica
fi
ngin
given
preengraft
period
associ
trend
suggest
abil
prevent
aspergillosi
trial
incid
ia
among
patient
receiv
micafungin
among
patient
receiv
fl
uconazol
p
taken
togeth
seem
moldact
azol
inde
reduc
incid
ia
fi
nding
howev
balanc
signi
fi
cantli
improv
abil
earli
detect
fungal
infect
potenti
undesir
consequ
includ
toxic
drugdrug
interact
cost
emerg
resist
applic
serial
serum
galactomannan
monitor
enabl
us
make
diagnosi
ia
much
earlier
signi
fi
cant
impact
reduc
mortal
inde
strategi
appli
recent
publish
rct
studi
allogen
hct
recipi
random
receiv
fl
uconazol
voriconazol
condit
day
patient
develop
gvhd
differ
previou
studi
screen
twiceweekli
serum
galactomannan
part
protocol
two
arm
appropri
antifung
therapi
start
base
posit
galactomannan
test
primari
endpoint
fungalfre
surviv
differ
two
arm
trend
lower
incid
ia
voriconazol
arm
similar
surviv
rate
therefor
data
suggest
give
antimold
agent
prophylaxi
give
fl
uconazol
plu
serial
monitor
serum
galactomannan
result
similar
outcom
therefor
sever
factor
taken
consider
determin
prophylaxi
appropri
speci
fi
c
treatment
center
given
patient
patient
popul
target
speci
fi
c
infect
prophylaxi
withheld
diagnosticbas
preemptiv
strategi
use
instead
secondari
prophylaxi
indic
patient
develop
invas
mold
infect
receiv
treatment
underli
malign
result
immunosuppress
particularli
neutropenia
andor
tcell
immunod
fi
cienci
option
secondari
prophylaxi
includ
amphotericin
b
lipid
formul
caspofungin
itraconazol
voriconazol
lipid
amphotericin
b
follow
voriconazol
addit
secondari
chemoprophylaxi
strategi
abbrevi
durat
neutropenia
use
reducedintens
condit
regimen
peripher
blood
stem
cell
use
granulocyt
transfus
may
employ
antifung
agent
dose
given
prophylaxi
summar
tabl
viral
infect
complic
cours
chemotherapi
patient
hematolog
malign
repres
reactiv
latent
infect
minor
due
exogen
acquisit
respiratori
virus
earli
cytomegaloviru
cmv
seroposit
allogen
hct
recipi
risk
viral
reactiv
onethird
patient
develop
cmv
diseas
mainli
pneumonia
high
fatal
rate
applic
preemptiv
therapi
guid
serial
monitor
cmv
antigenemia
markedli
reduc
incid
patient
develop
overt
manifest
die
cmv
pneumonia
recent
quantit
pcr
detect
cmv
dna
cmv
rna
introduc
altern
antigenemia
sinc
techniqu
sensit
antigenemia
threshold
start
preemptiv
therapi
establish
everi
group
patient
word
speci
fi
c
number
copi
cmv
dna
trigger
institut
preemptiv
therapi
allogen
hct
may
patient
less
sever
immunod
fi
cienci
inde
applic
sensit
biomark
reveal
host
thought
risk
cmv
reactiv
may
inde
posit
cmv
pcr
quit
frequent
outsid
set
allogen
hct
patient
higher
risk
develop
cmv
reactiv
includ
patient
cll
receiv
fl
udarabin
especi
alemtuzumab
patient
multipl
myeloma
receiv
highli
intens
therapi
autolog
hct
recipi
treat
previous
rituximab
two
strategi
report
effect
prophylaxi
cmv
diseas
allogen
hct
recipi
univers
prophylaxi
preemptiv
therapi
univers
prophylaxi
usual
given
strategi
may
lead
signi
fi
cant
increas
incid
bacteri
fungal
superinfect
associ
ganciclovirinduc
neutropenia
immunosuppress
occurr
late
cmv
diseas
ganciclovir
administ
intraven
drug
often
use
preemptiv
therapi
usual
durat
therapi
week
provid
antigenemia
pcr
becom
promptli
neg
otherwis
prolong
cours
ganciclovir
mainten
therapi
indic
altern
ganciclovir
includ
foscarnet
oral
valganciclovir
reactiv
hsv
frequent
patient
hematolog
malign
especi
induct
chemotherapi
acut
leukemia
follow
condit
regimen
hct
manifest
oral
lesion
indistinguish
chemotherapyinduc
mucos
less
frequent
manifest
includ
genit
ulcer
esophag
hepat
pneumonia
antivir
prophylaxi
hsv
administ
patient
seroposit
hsv
convey
histori
recurr
fever
blister
cold
sore
indic
recurr
hsv
infect
particularli
count
low
drug
choic
acyclovir
given
prior
time
cytotox
myeloabl
chemotherapi
continu
bone
marrow
recoveri
resolut
mucos
altern
acyclovir
valacyclovir
famciclovir
tabl
patient
highest
risk
vzv
reactiv
sever
lymphopenia
andor
cytopenia
patient
lymphoma
leukemia
mainli
cll
heavili
treat
myeloma
patient
hct
recipi
patient
receiv
fl
udarabin
alemtuzumab
without
acyclovir
prophylaxi
reactiv
vzv
common
complic
sever
postherpet
neuralgia
viscer
dissemin
pneumon
meningoenceph
hepat
may
rare
occur
sever
immunocompromis
patient
patient
high
risk
avoid
contact
person
vzv
diseas
well
vaccin
recipi
develop
rash
vaccin
addit
contact
airborn
precaut
recommend
immunocompromis
patient
develop
vzv
diseas
order
decreas
risk
transmiss
patient
hcw
highrisk
patient
histori
recent
contact
person
vzv
diseas
receiv
varicellazost
immunoglobulin
vzig
altern
acyclovir
valacyclovir
acyclovir
indic
prophylaxi
vzv
reactiv
allogen
hct
recipi
usual
given
year
addit
patient
multipl
myeloma
receiv
regimen
contain
bortezomib
receiv
prophylaxi
high
risk
vzv
reactiv
use
vzv
prophylaxi
set
debat
reserv
sever
immunosuppress
patient
especi
develop
herp
zoster
patient
epsteinbarr
viru
ebv
diseas
may
present
fever
mononucleosi
syndrom
addit
hct
recipi
may
present
posttranspl
lymphoprolif
diseas
ptld
patient
high
risk
ptld
includ
recipi
match
unrel
mismatch
tcell
deplet
transplant
recipi
high
dose
antithymocyt
globulin
antitcel
monoclon
antibodi
patient
acut
chronic
gvhd
receiv
radiat
part
condit
regimen
high
risk
patient
ebv
seroneg
advis
avoid
close
contact
ebv
seroposit
individu
increas
ebv
viral
load
follow
ppsctbmt
common
highest
patient
risk
ptld
best
strategi
prevent
pltd
serial
monitor
highrisk
patient
serum
quantit
pcr
techniqu
give
rituximab
preemptiv
patient
present
ebv
replic
patient
hematolog
malign
undergo
cytotox
chemotherapi
infect
hepat
b
viru
hbv
higher
risk
sever
liver
dysfunct
therapyinduc
aplasia
possibl
viral
replic
increas
dramat
result
acut
hbv
infect
may
mild
asymptomat
chronic
progress
lead
fulmin
hepat
fulmin
hepat
usual
coincid
discontinu
immunosuppress
risk
factor
reactiv
includ
male
gender
younger
age
diagnosi
lymphoma
posit
hbv
e
antigen
hct
recipi
risk
reactiv
high
although
chemotherapi
regimen
may
result
hbv
reactiv
risk
particularli
higher
exposur
corticosteroid
rituximab
alemtuzumab
patient
circul
hbv
dna
receiv
preemptiv
therapi
lamivudin
mgday
regimen
effect
rel
nontox
howev
prolong
exposur
lamivudin
may
result
develop
resist
optim
durat
preemptiv
therapi
establish
usual
recommend
least
month
discontinu
chemotherapi
avoid
viral
reactiv
develop
hepat
patient
infect
hepat
c
viru
hcv
may
receiv
chemotherapi
hct
without
major
complic
except
higher
risk
sinusoid
obstruct
syndrom
risk
patient
develop
late
cirrhosi
sever
year
hct
patient
hcv
assess
evid
chronic
liver
diseas
patient
cirrhosi
select
receipt
hct
receiv
convent
condit
regimen
although
oral
ribabvirin
may
clear
hcv
viremia
routin
use
prophylaxi
recommend
respiratori
virus
adenoviru
fl
uenza
parain
fl
uenza
rsv
rhinoviru
coronaviru
metapneumoviru
may
caus
infect
patient
hematolog
malign
infect
appear
selflimit
although
progress
sever
lower
respiratori
infect
may
occur
main
strategi
prophylaxi
infect
respiratori
virus
prevent
exposur
patient
hematolog
malign
individu
symptom
respiratori
infect
vaccin
household
contact
hcw
fl
uenza
recommend
fl
uenza
season
addit
patient
receiv
chemotherapi
also
receiv
vaccin
consid
may
respond
vaccin
intervent
safe
howev
consid
respons
vaccin
may
suboptim
chemoprophylaxi
neuraminidas
inhibitor
commun
outbreak
recommend
regard
rsv
parain
fl
uenza
viru
adenoviru
highli
immunosuppress
patient
may
risk
sever
pneumonia
formal
prophylaxi
avail
approv
therefor
prevent
sever
diseas
best
approach
earli
diagnosi
therapi
incid
tuberculosi
patient
hematolog
malign
low
even
highli
endem
region
studi
spain
incid
tuberculosi
signi
fi
cantli
higher
gener
popul
among
allogen
autolog
hct
recipi
anoth
studi
patient
hematolog
malign
brazil
retrospect
review
diagnosi
tuberculosi
preval
risk
factor
underli
diseas
associ
signi
fi
cant
impair
cmi
eg
receipt
fl
udarabin
corticosteroid
malnutrit
problem
patient
develop
tuberculosi
clearli
identi
fi
ed
risk
factor
patient
avoid
contact
person
activ
tuberculosi
well
environ
may
potenti
patient
tuberculosi
healthcar
facil
shelter
homeless
studi
test
antimicrobi
prophylaxi
high
risk
patient
recent
publish
guidelin
infect
prophylaxi
hct
recipi
recommend
use
isoniazid
mgkg
maximum
mgday
pyridoxin
mg
daili
month
immunosuppress
dosag
substanti
reduc
patient
past
histori
tuberculosi
exposur
someon
activ
tuberculosi
patient
posit
tuberculin
test
interferongamma
releas
assay
without
histori
bcg
vaccin
reactiv
latent
infect
common
mechan
pneumonia
pneumocysti
jirovecii
among
immunocompromis
patient
patient
high
risk
pneumocysti
jirovecii
pneumonia
pjp
chronic
tcell
immunod
fi
cienci
particularli
children
acut
lymphoid
leukemia
hct
recipi
patient
receiv
purin
analogu
monoclon
antibodi
corticosteroid
long
period
effect
drug
prophylaxi
tmpsmx
accept
dosag
includ
one
doublestrength
tablet
trimethoprim
mg
sulfamethoxazol
mg
bid
day
week
one
doublestrength
tablet
daili
time
week
one
singlestrength
tablet
trimethoprim
mg
sulfamethoxazol
mg
daili
time
initi
durat
prophylaxi
individu
accord
underli
diseas
type
treatment
exampl
patient
prophylaxi
usual
start
end
induct
period
discontinu
month
complet
mainten
therapi
hct
recipi
start
engraft
continu
long
immunosuppress
therapi
ongo
extens
gvhd
present
count
cellsmm
altern
agent
includ
aerosol
pentamidin
given
respirgard
ii
nebul
mg
everi
month
initi
load
dose
given
everi
week
atovaquon
suspens
mg
day
dapson
mg
bid
mgday
seroposit
patient
risk
reactiv
toxoplasmosi
follow
hct
recipi
donor
seroneg
special
precaut
taken
avoid
primari
infect
precaut
includ
eat
wellcook
meat
well
wash
veget
cook
egg
pasteur
milk
steril
water
handwash
outdoor
activ
handl
raw
meat
veget
use
glove
contact
soil
garden
avoid
contact
cat
litter
someon
chang
litter
box
daili
soak
boil
water
min
reactiv
toxoplasmosi
highest
among
recipi
tcell
deplet
allogen
psctbmt
otherwis
rare
among
allogen
recipi
potenti
toxic
effect
agent
preclud
routin
prophylaxi
toxoplasmosi
howev
preemptiv
therapi
highrisk
patient
posit
serolog
prior
transplant
tcell
deplet
allogen
transplant
pcrbase
test
recommend
primari
prophylaxi
may
consid
patient
histori
ocular
toxoplasmosi
effect
prophylaxi
includ
tmpsmx
one
doublestrength
tablet
daili
time
week
one
singlestrength
tablet
daili
clindamycin
mg
thrice
daili
plu
pyrimethamin
mgday
plu
leucovorin
mg
pyrimethaminesulfadoxin
fansidar
one
tablet
mg
mg
sulfadoxin
kg
weight
day
folin
acid
kg
day
daili
follow
engraft
atovaquon
mgday
dapson
mgday
plu
pyrimethamin
mgweek
plu
folin
acid
mgweek
fansidar
associ
signi
fi
cant
toxic
strongyloid
stercorali
may
caus
fatal
dissemin
syndrom
intestin
larval
invas
bacteri
superinfect
patient
high
risk
tcell
immunod
fi
cienci
patient
risk
avoid
contact
outhous
cutan
exposur
soil
surfac
might
contamin
human
fece
addit
patient
unexplain
eosinophilia
live
resid
travel
endem
area
screen
either
stool
examin
stool
examin
enzymelink
immunosorb
assay
elisa
patient
whose
screen
posit
receiv
empir
treatment
ivermectin
gkgday
day
repeat
week
passiv
immun
iv
immunoglobulin
ivig
intraven
immunoglobulin
may
bene
fi
patient
cll
nonhodgkin
lymphoma
myeloma
sever
hypogammaglobulinemia
serum
igg
level
mg
dl
recurr
andor
sever
infect
despit
appropri
antimicrobi
prophylaxi
immun
dose
ivig
mgkg
everi
week
shown
effect
mgkg
everi
week
howev
role
ivig
prevent
infect
among
patient
hematolog
malign
clear
unlik
superior
antibiot
prophylaxi
see
earlier
section
antibacteri
prophylaxi
among
hct
recipi
major
bene
fi
ivig
reduct
acut
gvhd
allogen
hct
administr
ivig
prevent
infect
among
patient
sever
hypogammaglobulinemia
serum
igg
mgdl
commonli
practic
unproven
valu
immun
patient
hematolog
malign
undergo
cytotox
chemotherapi
three
goal
maintain
appropri
adult
immun
schedul
b
restor
immun
could
lost
immunosuppress
treatment
c
protect
patient
receipt
live
vaccin
suggest
schedul
immun
hct
shown
tabl
granulocyt
colonystimul
factor
gcsf
shown
reduc
incid
fever
durat
antibiot
therapi
hospit
studi
howev
signi
fi
cant
reduct
cultureproven
infect
mortal
shown
best
costeffect
prophylact
use
gcsf
set
risk
febril
neutropenia
prophylact
gmcsf
gcsf
elicit
granulocyt
transfus
remain
investig
may
consid
patient
histori
neutropeniarel
invas
mold
infect
aspergillosi
fusariosi
expect
neutropen
day
infect
frequent
complic
lead
caus
morbid
mortal
patient
hematolog
malign
gener
higher
risk
certain
infect
bene
fi
cial
like
prophylaxi
likewis
shorter
period
risk
therefor
predict
durat
prophylaxi
higher
possibl
prophylaxi
work
decis
give
prophylaxi
take
account
potenti
bene
fi
ts
also
side
effect
cost
induct
resist
potenti
drug
interact
antineoplast
drug
risk
assess
key
element
de
fi
ning
prophylact
strategi
